Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
NBA playoffs: Edwards leads Wolves to 98
Netanyahu, Biden talk over hostages, aid to Gaza
IAEA chief stresses further monitoring of Fukushima nuke wastewater discharge
Homicide suspect kills himself after fleeing through 3 states, authorities say
What a blast to work at NASA. Space agency is sky
Arab states condemn U.S. for vetoing UNSC resolution on Gaza ceasefire
Hamas leader arrives in Cairo to hold talks on Gaza truce
Bogusz scores in each half as LAFC notches 2
With Djokovic awaiting the winner, Murray trails Hanfmann at rain
Africa Energy Indaba highlights prospects of South Africa
Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
Day 3 of the Masters at a glance